Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinomaYair Lotan; Vitaly Margulis)
European Journal of Surgical Oncology. 2014;40(1):113-120.Abstract
Aims Evidence suggests a detrimental effect of diabetes mellitus (DM) on cancer incidence and outcomes. To date, the effect of DM and its treatment on prognosis in upper tract urothelial carcinoma (UTUC) remains uninvestigated. We tested the hypothesis that DM and metformin use impact oncologic outcomes of patients treated with radical nephroureterectomy (RNU) for UTUC. Methods Retrospective analysis of 2492 patients with UTUC treated at 23 institutions with RNU without neoadjuvant therapy. Cox regression models addressed the association of DM and metformin use with disease recurrence, cancer-specific mortality and any-cause mortality. Results A total of 365 (14.3%) patients had DM and 194 (7.8%) patients used metformin. Within a median follow-up of 36 months, 663 (26.6%) patients experienced disease recurrence, 545 patients (21.9%) died of UTUC and 884 (35.5%) patients died from any cause. Diabetic patients who did not use metformin were at significantly higher risk of disease recurrence and cancer-specific death compared to non-diabetic patients and diabetic patients who used metformin. In multivariable Cox regression analyses, DM treated without metformin was associated with worse recurrence-free survival (HR: 1.44, 95% CI 1.10-1.90, p = 0.009) and cancer-specific mortality (HR: 1.49, 95% CI 1.11-2.00, p = 0.008). Conclusions Diabetic UTUC patients without metformin use have significantly worse oncologic outcomes than diabetics who used metformin and non-diabetics. The possible mechanism behind the impact of DM on UTUC biology and the potentially protective effect of metformin need further elucidation. © 2013 Elsevier Ltd. All rights reserved.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Richard Zigeuner; Shahrokh F. Shariat; Vitaly Margulis; Pierre I. Karakiewicz; Marco Roscigno; Alon Weizer; Eiji Kikuchi; Mesut Remzi; Jay D. Raman; Christian Bolenz; et al.European Urology. 2010;57(4):575-581.
Michael Rink; Brian D. Robinson; David A. Green; Eugene K. Cha; Jens Hansen; Evi Comploj; Vitaly Margulis; Jay D. Raman; Casey K. Ng; Mesut Remzi; et al.Journal of Urology. 2012;188(2):398-404.
Jay D. Raman; Shahrokh F. Shariat; Pierre I. Karakiewicz; Yair Lotan; Arthur I. Sagalowsky; Marco Roscigno; Francesco Montorsi; Christian Bolenz; Alon Z. Weizer; Jeffery C. Wheat; et al.Urologic Oncology: Seminars and Original Investigations. 2011;29(6):716-723.
Appears in this Document